In fact, the analysis of 200 ERBB2-amplified tumors showed that the SRCIN1 gene is often (55–60% of ERBB2-amplified breast cancer patients), but not necessarily co-amplified with ERBB2. Here, SRCIN1 is linked to breast carcinoma.